

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)



(10) International Publication Number
WO 2022/207580 A3

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 31/502 (2006.01)
A61K 9/107 (2006.01) A61K 31/5377 (2006.01)
A61K 31/05 (2006.01) A61K 31/553 (2006.01)
A61K 31/12 (2006.01) A61K 31/58 (2006.01)
A61K 31/192 (2006.01) A61K 31/7135 (2006.01)
A61K 31/196 (2006.01) A61K 38/12 (2006.01)
A61K 31/216 (2006.01) A61K 47/14 (2017.01)
A61K 31/4025 (2006.01) A61K 47/12 (2006.01)
A61K 31/4184 (2006.01) A61K 47/28 (2006.01)
A61K 31/436 (2006.01) A61K 31/4418 (2006.01)
A61K 31/44 (2006.01) A61K 31/496 (2006.01)
A61K 31/4453 (2006.01)

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2022/058180

(22) International Filing Date:

28 March 2022 (28.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/166,995 27 March 2021 (27.03.2021) US
63/269,330 14 March 2022 (14.03.2022) US

(71) Applicant: **TRX BIOSCIENCES LIMITED** [GB/GB];
The Walbrook Building, 25 Walbrook, London EC4N 8AF (GB).

(72) Inventors: **GOODING, Daniel**; C/O TRx Biosciences Limited, The Walbrook Building, 25 Walbrook, London EC4N 8AF (GB). **BREW, John**; C/O TRx Biosciences Limited, The Walbrook Building, 25 Walbrook, London EC4N 8AF (GB). **BANNISTER, Robin M.**; C/O TRx Biosciences Limited, The Walbrook Building, 25 Walbrook, London EC4N 8AF (GB).

(74) Agent: **SCHLICH, George William**; 9 St. Catherine's Road, Littlehampton West Sussex BN17 5HS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

29 December 2022 (29.12.2022)

(54) Title: COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY OF THERAPEUTICS

(57) Abstract: The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C₁₄₋₂₄ fatty acids, one or more free C₁₄₋₂₄ fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.

WO 2022/207580 A3